Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 14/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934731 | 1.00 | CSNK2B (0.47) | CSNK2BGSK3BNPC1RAB9ACSNK2A1 | |
| SCHEMBL12645615 | 0.90 | CSNK2B (0.39) | CSNK2BGSK3BNPC1RAB9ACSNK2A1 | |
| SCHEMBL2030256 | 0.89 | CSNK2B (0.42) | CSNK2BGSK3BCSNK2A1CSNK2A2MAPT | |
| SCHEMBL2030258 | 0.89 | CSNK2B (0.42) | CSNK2BGSK3BCSNK2A1CSNK2A2MAPT | |
| SCHEMBL1934502 | 0.88 | CSNK2B (0.43) | CSNK2B | |
| SCHEMBL12644795 | 0.88 | CSNK2B (0.43) | CSNK2B | |
| SCHEMBL1934500 | 0.88 | CSNK2B (0.43) | CSNK2B | |
| SCHEMBL14242858 | 0.88 | CSNK2B (0.41) | CSNK2BGSK3BCSNK2A1CSNK2A2MAPT | |
| SCHEMBL1934403 | 0.86 | CSNK2B (0.40) | CSNK2B | |
| SCHEMBL19527161 | 0.85 | GSK3B (0.40) | CSNK2BGSK3BNPC1RAB9ACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| WO-2012170827-A2 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | CSNK2B 13/4885GSK3B 537/4885NPC1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.